NHS warns parents of virus dangerous to newborns after surge in Australia
And following a surge in cases number of respiratory syncytial virus (RSV) cases in Australia, officials have said that cases have been steadily increasing in England since the start of 2025.
NHS England has urged pregnant women to get the vaccine which protects against RSV in order to protect their newborn babies.
It said that the virus is a leading cause of death among babies and the main cause of hospital admissions for children.
Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation.
'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.'
Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery.
Older adults aged 75-79 are also eligible for the jab and NHS England will start inviting people to come forward in the next few weeks.
RSV is a common cause of coughs and colds.
But some people have a high risk of getting seriously ill from the virus including babies and adults over the age of 75.
In babies, RSV is a common cause of a type of chest infection called bronchiolitis.
Last week, the UK Health Security Agency published data showing the efficacy of the vaccine.
It said that the jab for pregnant women can prevent 72pc of hospital admissions for their babies.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Agriland
4 hours ago
- Agriland
Australia Develops World First Biodegradable Vaccine for Fmd
By Chris McCullough The world's first biodegradable vaccine for foot-and-mouth disease (FMD) has been developed in Australia, a country that remains free from the dreaded livestock killer for over 150 years. FMD is a highly infectious viral disease that affects cattle, sheep, goats, and pigs. It remains widespread globally and is endemic in many countries, particularly in Africa, Asia and Middle East. More recently, FMD has appeared on a number of farms in Europe, with the disease detected in cattle in Germany, Hungary and Slovakia. Even though Australia remains FMD free, it recognises how much damage the disease could do, if it were to appear there. The Australian Bureau of Agricultural and Resource Economics and Sciences (ABARES) has estimated an FMD incursion could cost the Australian economy up to $80 billion, which would have a catastrophic impact on trade, animal welfare and farm productivity. This breakthrough in vaccine development was made possible through a $20 million, five-year research partnership between Meat & Livestock Australia, Tiba Biotech, and the New South Wales Government. The vaccine has taken less than 18 months to develop and has cost about $2.5 million. MLA managing director, Michael Crowley, said while it was hoped that an FMD vaccine would never be needed, the research represented a proactive approach to managing biosecurity risk. Crowley said: 'FMD is present in countries near to Australia and is front of mind for industry in terms of potential biosecurity risks. 'Vaccination may not necessarily be required in the event of a disease incursion, but this research demonstrates that the Australian industry is proactive and prepared.' Australia has developed the world's first biodegrable vaccine for FMD, which is endemic in many countries, particularly Africa, Asia and Middle East. Researchers found that the new vaccine demonstrated strong, effective immune response and safety in preliminary trials in Germany. Vaccinated cattle did not contract FMD when exposed to the disease and, importantly, they did not shed the virus. The new biodegradable vaccine uses mRNA to induce an immune response, rather than an actual virus. mRNA vaccines have been proven safe for animals and for consumers according to the researchers. Following these trials, the vaccine must now undergo a rigorous evaluation process with the Australian Pesticides and Veterinary Medicines Authority (APVMA) before approval for use on livestock. New South Wales (NSW) Minister for Agriculture, Tara Moriarty, said: 'The delivery of an FMD vaccine is part of the Minns Government's commitment to safeguarding livestock from key biosecurity threats and ensuring the state's agriculture industry can thrive. 'Developing local capacity to produce vaccines against emergency animal diseases is a critical priority for the NSW government, Australia's livestock industries and our economy.' mRNA vaccines allow the animal to create proteins and antibodies to trigger an immune response. They do this without entering the nucleus of cells and disappear from the animal within days, leaving antibodies behind for protection against the virus. Australian-based Tiba co-founder, Peter McGrath, added: 'Australia is now at the forefront of livestock vaccine development, bringing with it the potential to develop manufacturing capacity, jobs, and exports. 'Unlike current mRNA technologies, our vaccines can be stored long-term at standard refrigeration temperatures and even at room temperature for at least one month, which is a critical advantage in livestock applications.' The project is also conducting similar research to develop a vaccine for lumpy skin disease, which is also a significant exotic disease threat to Australia. The project has also included input from the Queensland Department of Agriculture and Fisheries, the German Friedrich-Loeffler-Institut and Canadian Food Inspection Agency.
Irish Examiner
14 hours ago
- Irish Examiner
Concern over weight gain after 'skinny jabs'
Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming off the drugs should be given support to help prevent them piling on the pounds again. Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered "structured advice and follow-up support" to help prevent weight gain. The guidance is for people who are offered the treatments through Britain's NHS. An estimated 1.5 million people are taking weight loss jabs in Britain, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. The new "quality standard" from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building "long-term behavioural habits, use self-monitoring tools, and draw on wider support — from online communities to family-led interventions and local activities". "Successful weight management doesn't end when medication stops or when someone completes a behavioural programme," said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. "We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: "Weight management is a long-term journey, not a short-term fix. "The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. "We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. "This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. Henry Gregg, chief executive of the National Pharmacy Association, said: "We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable." Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: "There is no one-size-fits-all approach to tackling obesity — what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. "It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. "As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services — particularly for when patients come off their medication — will be key to optimal health outcomes."
Irish Independent
17 hours ago
- Irish Independent
NHS warns parents of virus dangerous to newborns after surge in Australia
NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. And following a surge in cases number of respiratory syncytial virus (RSV) cases in Australia, officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the vaccine which protects against RSV in order to protect their newborn babies. It said that the virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said: 'While for most adults RSV only causes mild, cold-like symptoms, for older adults and young children it can lead to serious breathing problems that can end up in hospitalisation. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab and NHS England will start inviting people to come forward in the next few weeks. RSV is a common cause of coughs and colds. But some people have a high risk of getting seriously ill from the virus including babies and adults over the age of 75. In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It said that the jab for pregnant women can prevent 72pc of hospital admissions for their babies.
